NASDAQ:TPTX Turning Point Therapeutics (TPTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$76.01▼$76.0150-Day Range$74.80▼$76.0152-Week Range$23.77▼$82.20Volume4,322 shsAverage Volume1.14 million shsMarket Capitalization$3.81 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Turning Point Therapeutics alerts: Email Address Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Turning Point Therapeutics Stock (NASDAQ:TPTX)Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.Read More Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! TPTX Stock News HeadlinesJuly 25 at 9:38 AM | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call TranscriptFebruary 17, 2024 | wsj.comTurning Point Brands Inc.July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.February 12, 2024 | bbc.co.ukAlzheimer’s: A Turning Point?February 10, 2024 | investing.comTurning Point Brands Inc (TPB)February 10, 2024 | benzinga.comCormorant Asset Management, LP's Net WorthJanuary 15, 2024 | bbc.co.ukSolving quadratic equations - EdexcelDecember 19, 2023 | morningstar.comCOP15: A Turning Point for Investor Approaches to BiodiversityJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.December 16, 2023 | bbc.comTurning Point USA: Are conservatives fighting back on campus?July 29, 2023 | ft.comTattoos have reached a turning point at workJuly 11, 2023 | newsweek.comTurning Point USAJune 23, 2023 | health.usnews.comTurning Point HospitalJune 5, 2023 | bbc.co.ukCan Vinicius episode be a turning point in football’s racism battle?May 24, 2023 | usnews.comTurning Point Secondary SchoolApril 12, 2023 | ca.finance.yahoo.com2023 could be turning point for office-to-housing conversions: ColliersMarch 22, 2023 | theguardian.comThe invasion of Iraq was a turning point on to a path that led towards UkraineMarch 22, 2023 | news.yahoo.comPutin's arrest warrant is turning point – ZelenskyySee More Headlines Receive TPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TPTX CUSIPN/A CIK1595893 Webwww.tptherapeutics.com Phone(858) 926-5251FaxN/AEmployees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-236,550,000.00 Net MarginsN/A Pretax Margin-33,959.03% Return on Equity-37.45% Return on Assets-35.62% Debt Debt-to-Equity RatioN/A Current Ratio16.83 Quick Ratio16.83 Sales & Book Value Annual Sales$30.83 million Price / Sales123.46 Cash FlowN/A Price / Cash FlowN/A Book Value$15.84 per share Price / Book4.80Miscellaneous Outstanding Shares50,074,000Free Float45,768,000Market Cap$3.81 billion OptionableNot Optionable Beta-0.18 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Athena Maria Countouriotis M.D. (Age 50)Pres, CEO & Director Comp: $1.19MMr. Paolo Tombesi (Age 58)Exec. VP & CFO Comp: $741.19kDr. Mohammad Hirmand (Age 52)Exec. VP & Chief Medical Officer Comp: $783.77kMr. Ed GemoSr. VP & Chief Information OfficerDr. Gavin Hirst Ph.D.Sr. VP of Chemistry & Interim Chief Scientific OfficerDr. Adam D. Levy M.B.A.Ph.D., Sr. VP of Investor Relations & Corp. CommunicationsMr. Raymond J. Furey J.D. (Age 54)Sr. VP & Chief Compliance Officer Mr. Brian Sun J.D. (Age 38)M.S., Sr. VP, Gen. Counsel & Corp. Sec. Ms. Heather AdamsSr. VP of HRDr. Jeffrey P. WhittenSr. VP of Pre-Clinical Devel.More ExecutivesKey CompetitorsForty SevenNASDAQ:FTSVPTC TherapeuticsNASDAQ:PTCTSchrödingerNASDAQ:SDGRReata PharmaceuticalsNASDAQ:RETASage TherapeuticsNASDAQ:SAGEView All Competitors TPTX Stock Analysis - Frequently Asked Questions How were Turning Point Therapeutics' earnings last quarter? Turning Point Therapeutics, Inc. (NASDAQ:TPTX) posted its earnings results on Tuesday, November, 9th. The company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by $0.08. The firm had revenue of $0.46 million for the quarter. When did Turning Point Therapeutics IPO? Turning Point Therapeutics (TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What other stocks do shareholders of Turning Point Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV) and Gilead Sciences (GILD). This page (NASDAQ:TPTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turning Point Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turning Point Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.